CheckMate 9LA: 2-Yr Update of First-line Nivolumab + Ipilimumab With 2 Cycles of Chemotherapy vs Chemotherapy Alone in Advanced NSCLC

June 4-8, 2021; Online at https://conferences.asco.org/am
First-line nivolumab plus ipilimumab with chemotherapy continued to provide durable clinical benefit in patients with advanced NSCLC regardless of PD-L1 expression with extended follow-up.
Format: Microsoft PowerPoint (.ppt)
File Size: 562 KB
Released: June 10, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Related Content

Concise interactive module featuring Helena A. Yu, MD, on the role of HER3 in lung cancer, from Clinical Care Options (CCO)

Helena A. Yu, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: October 27, 2021 Expired: October 26, 2022

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Text module presenting a pharmacist’s perspective on toxicities with neoadjuvant/adjuvant immunotherapy for early-stage NSCLC from Clinical Care Options (CCO)

Stefanie Houseknecht, PharmD, BCOP Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: October 13, 2021 Expired: October 12, 2022

Slideset presenting a pharmacist’s perspective on toxicities with neoadjuvant/adjuvant immunotherapy for early-stage NSCLC from Clinical Care Options (CCO)

Stefanie Houseknecht, PharmD, BCOP Released: October 13, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue